<DOC>
	<DOCNO>NCT03040973</DOCNO>
	<brief_summary>The rollover study provide continue treatment assessment long-term safety follow-up patient receive capmatinib ( INC280 ) Novartis sponsor study opinion Investigator would benefit continued treatment .</brief_summary>
	<brief_title>Roll-over Study Patients With cMET-dependent Malignancies Who Previously Completed Novartis Capmatinib Study</brief_title>
	<detailed_description />
	<criteria>Patient currently receive treatment INC280 monotherapy within Novartissponsored study fulfil requirement primary objective , opinion Investigator , would benefit continued treatment . Willingness ability comply schedule visit , treatment plan study procedure . Written inform consent obtain prior enrol rollover study receive study medication . If consent express writing , must formally document witnessed , ideally via independent trusted witness . Patient previously permanently discontinue INC280 study treatment parent study due reason . Patient currently unresolved toxicity INC280 dosing interrupt parent study ( Patients meeting eligibility criterion may enrol toxicity resolve allow INC280 dosing resume ) . Pregnant nursing ( lactate ) woman . Women childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception dose 7 day stop treatment . Sexually active male unless use condom intercourse take drug 7 day stop treatment .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>capmatinib</keyword>
	<keyword>cMET</keyword>
	<keyword>advanced solid tumor</keyword>
	<keyword>cancer</keyword>
</DOC>